In the intratibial LNCaP xenograft model, the effects of the combination of darolutamide and radium-223 were prominent, along with decreases in both serum PSA levels and areas of tumor-induced abnormal bone, while radium-223 or darolutamide alone did not reduce serum PSA levels. Here, KLK3 is linked to neoplasm.